RxDoctor Payments DataLook up a doctor →

Charles Ugokwe, MD

Neurology · Alexandria, LANPI 1144210717

Payments from drug & device makers

$70,143in general payments, 2019–2025

Across 1,404 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$20K
  • AbbVie$8K
  • Biogen$7K
  • UCB, Inc.$7K
  • Neurelis, Inc.$5K
  • Sanofi$3K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.114$20,222
AbbVie(2 entities)106$8,190
Biogen73$6,654
UCB, Inc.156$6,567
Neurelis, Inc.58$5,172
Sanofi67$2,938
Neurocrine Biosciences, Inc.129$2,300
Argenx US, Inc.15$2,050
MDD US Operations, LLC15$1,899
EMD Serono, Inc.49$1,425
Teva Pharmaceuticals USA, Inc.72$1,378
SK Life Science, Inc.64$1,056
Aquestive Therapeutics, Inc.5$885
Sunovion Pharmaceuticals Inc.77$804
Novartis48$726
Jazz Pharmaceuticals Inc.19$621
Greenwich Biosciences, Inc.18$563
Amgen(2 entities)16$534
Sumitomo Pharma America, Inc.24$406
Zogenix Inc.44$391
Bristol Myers Squibb21$336
E.r. Squibb & Sons, L.L.C.4$326
TG Therapeutics, Inc.8$273
Mallinckrodt Hospital Products Inc.14$271
Harmony Biosciences LLC9$267
Genentech USA, Inc.15$259
Immedica Pharma US, Inc.11$247
Lundbeck LLC11$242
Pfizer12$229
Lilly USA, LLC10$219
Biomarin Pharmaceutical Inc.6$189
Acadia Pharmaceuticals Inc9$185
Otsuka America Pharmaceutical, Inc.5$177
Biohaven Pharmaceuticals, Inc.11$171
Sarepta Therapeutics, Inc.8$166
Johnson & Johnson7$161
Advanced Respiratory, Inc4$148
Biohaven Pharmaceutical Holding Company Ltd.4$130
Esperion Therapeutics, Inc.1$125
Baxter Healthcare7$119
Livanova USA, Inc.5$109
Catalyst Pharmaceuticals, Inc.5$105
Adamas Pharmaceuticals, Inc.4$96
Alnylam Pharmaceuticals Inc.5$83
Kyowa Kirin, Inc.4$81
Grifols USA, LLC4$78
AstraZeneca4$72
Supernus Pharmaceuticals, Inc.4$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$58
Janssen Scientific Affairs, LLC2$54
Akcea Therapeutics, Inc.3$53
Amneal Pharmaceuticals LLC3$49
Pyros Pharmaceuticals, Inc.2$40
Currax Pharmaceuticals LLC3$37
ANI Pharmaceuticals, Inc.1$29
Cycle Pharmaceuticals Inc1$27
Boston Scientific1$20
Hospira, Inc.2$20
Xeris Pharmaceuticals, Inc.1$16
Aucta Pharmaceuticals, Inc.1$16

How this compares

$70,143 in reported general payments places this provider in the 90th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$141,946
Medicare patients
430
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →